GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China SXT Pharmaceuticals Inc (NAS:SXTC) » Definitions » Net-Net Working Capital

China SXT Pharmaceuticals (China SXT Pharmaceuticals) Net-Net Working Capital : $4.37 (As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is China SXT Pharmaceuticals Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

China SXT Pharmaceuticals's Net-Net Working Capital for the quarter that ended in Sep. 2023 was $4.37.

The industry rank for China SXT Pharmaceuticals's Net-Net Working Capital or its related term are showing as below:

SXTC's Price-to-Net-Net-Working-Capital is ranked better than
99.27% of 411 companies
in the Drug Manufacturers industry
Industry Median: 7.02 vs SXTC: 0.26

China SXT Pharmaceuticals Net-Net Working Capital Historical Data

The historical data trend for China SXT Pharmaceuticals's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China SXT Pharmaceuticals Net-Net Working Capital Chart

China SXT Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Net-Net Working Capital
Get a 7-Day Free Trial 564.56 -98.28 -46.47 17.36 8.26

China SXT Pharmaceuticals Semi-Annual Data
Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -163.52 17.36 -10.41 8.26 4.37

Competitive Comparison of China SXT Pharmaceuticals's Net-Net Working Capital

For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China SXT Pharmaceuticals's Price-to-Net-Net-Working-Capital Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where China SXT Pharmaceuticals's Price-to-Net-Net-Working-Capital falls into.



China SXT Pharmaceuticals Net-Net Working Capital Calculation

China SXT Pharmaceuticals's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Mar. 2023 is calculated as

Net-Net Working Capital(A: Mar. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(17.368+0.75 * 1.345+0.5 * 0.531-14.863
-0-0)/0.45736
=8.26

China SXT Pharmaceuticals's Net-Net Working Capital (NNWC) per share for the quarter that ended in Sep. 2023 is calculated as

Net-Net Working Capital(Q: Sep. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(11.465+0.75 * 1.311+0.5 * 0.493-9.512
-0-0)/0.72785
=4.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


China SXT Pharmaceuticals  (NAS:SXTC) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


China SXT Pharmaceuticals Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of China SXT Pharmaceuticals's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


China SXT Pharmaceuticals (China SXT Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
No. 178 Taidong Road North, Jiangsu, Taizhou, CHN, 225300
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, Advanced TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates a majority of its revenue from the People's Republic of China.

China SXT Pharmaceuticals (China SXT Pharmaceuticals) Headlines

From GuruFocus

China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split

By GuruFocusNews GuruFocusNews 05-18-2022